levels of interleukin-10 (IL-10), elevated serum vitamin B12 and hypergammaglobulinaemia; however, these latter findings are not diagnostic (Rieux-Laucat et al, 2003) .
Most patients with ALPS develop autoimmunity, usually manifested as autoimmune cytopenias. Other autoimmune manifestations are seen less frequently, including autoimmune nephritis, hepatitis, arthritis, colitis, uveitis and urticaria (Sneller et al, 1997) . Some patients with ALPS require no treatment; however, many other patients require medications directed toward autoimmune manifestations, particularly autoimmune cytopenias. Patients usually respond to short bursts of immunosuppressive medications, including corticosteroids (Bleesing et al, 2000) . Occasionally patients with severe cytopenias need more aggressive immunosuppression. Anecdotal reports and small series have described responses to a number of medications, including cyclosporine, mycophenolate mofetil (MMF), vincristine and rituximab (Ferrer et al, 2007) . Nevertheless, these agents are often ineffective, have significant side effects and are non-specific for ALPS.
Sirolimus (rapamycin) is an immunosuppressive agent that targets the mammalian target of rapamycin (mTOR) and has been shown to induce apoptosis in both normal and abnormal lymphocytes. We hypothesized that targeting the mTOR pathway might be effective in patients with ALPS by inducing apoptosis in the abnormal lymphocytes underlying this condition. We previously tested this hypothesis using two murine models of ALPS (CBA-lpr cg and MRL-lpr) and found sirolimus was more effective than conventional therapies, including MMF (Teachey et al, 2006) . Based on these results, we began treating children with refractory ALPS with sirolimus, targeting a serum trough level of 4-15 ng/ml. We have treated six patients and found marked improvement in autoimmune disease markers in all of these patients.
Results
Patients with ALPS were followed under an Institutional Review Board-approved classification protocol that allowed data collection, including medication response. We treated six male ALPS patients with sirolimus. Patients were started on sirolimus at 2-3 mg/m 2 /d, rounding to the nearest 0AE5 mg with maximum initial dose of 4 mg. Doses were adjusted to achieve a steady-state serum trough of 4-15 ng/ml. Three of these patients were type Ia because they have a documented mutation in FAS. The other three were classified as type III because no genetic mutation was found. Four corticosteroidrefractory or intolerant patients were treated for severe chronic autoimmune cytopenias. Three of the four patients had complete resolution of autoimmune cytopenias (Table I and Fig 1) . The fourth patient had near complete resolution with a residual mild thrombocytopenia (platelet count >100 · 10 9 /l).
All four patients were able to completely taper off steroids within 4 weeks of initiating sirolimus. These patients have been treated for 5, 7, 17 and 27 months. Many of these patients had failed other immunosuppressive medications, including MMF ( Table I ). Two of the six patients were treated with sirolimus for autoimmune arthritis and colitis for 6 and 36 months respectively. Both of these patients had marked improvement in their symptoms on sirolimus after failing multiple other immunosuppressant medications. One of these patients remains on low dose every other day steroids (Patient 5) without toxicity. Prior to sirolimus he required high dose steroids (1-2 mg/kg/d) with significant side effects. The other patient (Patient 6) required re-initiation of steroids after one year and other more aggressive immunosuppressive regimens were tried, including systemic chemotherapy (mercaptopurine, cyclophosphamide and methotrexate) and biological agents (anakindra, etanercept, rituximab and MMF) with and without sirolimus. No regimen controlled his disease as well as a combination of sirolimus and steroids and whenever his sirolimus was held for alternative regimens his disease would flare significantly. Thus, he has been continued on chronic sirolimus. Five patients had significant lymphoproliferation (lymphadenopathy and/or splenomegaly) at the initiation of sirolimus therapy. One patient's lymphoproliferation was controlled with steroids and thus he had no measurable lymphadenopathy or splenomegaly when sirolimus was initiated; he has not developed lymphoproliferation on sirolimus after stopping steroids. Of the five patients with lymphoproliferation at the time of sirolimus initiation, one patient had minimal response (no change in lymphadenopathy and mild improvement in splenomegaly), three patients had a complete response and one patient had a near-complete response with one 0AE5-cm residual cervical lymph node. One patient had positive disease on a positron emission tomography (PET)/computed tomography (CT) scan immediately prior to initiating sirolimus; a followup scan after 3 months of treatment demonstrated resolution of PET-avid disease (Fig 1) . We know of no other reported therapy producing such a dramatic response in refractory ALPS patients. As a biological marker of disease response, we compared peripheral blood DNTs prior to and after starting therapy with sirolimus. The percentage of DNTs was reduced by >50% in five of six patients (Fig 1) with an average decrease of 60% (P = 0AE02) (range 41-74%). Of note, despite the reduction in DNTs, no patient had a reduction in total absolute lymphocyte count (ALC). Three patients were mildly lymphopenic at the initiation of sirolimus and two of these (Patients 1 and 3) had improvement of ALC to the normal range. No grade 3 or 4 toxicities were observed in any patient.
Discussion
Sirolimus (rapamycin) is a Federal Drug Administrationapproved immunosuppressant that targets mTOR. Sirolimus has been in clinical use for over 20 years and its toxicities are well-described (Abdel-Karim & Giles, 2008) . We hypothesized that mTOR inhibitors would be effective in patients with ALPS for three compelling reasons: (i) mTOR inhibitors induce cell death and apoptosis in abnormal lymphocytes; (ii) mTOR inhibitors, unlike most other immunosuppressive medications, increase peripheral blood regulatory T cells (Tregs) and (iii) mTOR inhibitors are safe and well-tolerated.
Common toxicities found in patients taking sirolimus include hypercholesterolemia, hypertension and mucositis (Abdel-Karim & Giles, 2008 ). An increased risk of infections is very rare when used as a single agent; however, when combined with other immunosuppressive agents the risk increases. Sirolimus requires therapeutic drug monitoring to maximize effect and avoid toxicity.
Treatment for patients with refractory ALPS is challenging. Many patients do not require chronic treatment, but for those patients who do there are only a few effective and tolerable agents. Currently a number of more targeted therapies are undergoing preclinical testing and clinical trials. Pyrimethamine and sulphadoxine were shown to reduce lymphoproliferation and autoimmune cytopenias significantly in a small series of patients with ALPS; however, this combination failed to show any response in a different larger clinical trial (Ferrer et al, 2007) . We have also recently shown that targeting the Notch signaling pathway may be beneficial in preclinical models of ALPS (Teachey et al, 2008) , while other groups have shown that arsenic and histone deacetylase-inhibitors may be effective in preclinical models of ALPS (Ferrer et al, 2007) . As Patient 3 also had recurrent oral Herpes simplex virus flares and Epstein-Barr virus reactivation that resolved with initiation of sirolimus. àSirolimus can cause mild thrombocytopenia from bone marrow suppression. Patients 4 and 5 had mild residual thrombocytopenias (platelet count >100 · 10 9 /l) that could be immune-mediated or a drug side effect. §Patient 6 developed a pulmonary embolism while on steroids and sirolimus, most likely caused by steroids and inflammatory nature of his disease. Sirolimus is not reported to increase the risk of venous thromboembolism without concurrent microangiopathy. He had a negative anti-phospholipid antibody screen and no evidence of microangiopathy. with many autoimmune diseases, rituximab has been shown to be effective in a subset of ALPS patients; however, 5-10% of ALPS patients eventually develop common variable immunodeficiency (CVID) and our group (unpublished observations) and others have seen an association between rituximab use and the development of CVID in ALPS patients (Dale et al, 2007) . Moreover, the effects of rituximab are generally relatively transient; patients that do respond will probably relapse and with the potential risk of CVID, we recommend avoiding use of rituximab in ALPS patients. MMF was found to be effective in another series (Koneti Rao et al, 2005 ). While we have had less success overall with this drug, we have also seen good responses in a few children with ALPS treated with MMF (unpublished data).
MMF inhibits lymphocyte proliferation but does not cause lymphocyte death and does not appear to increase Tregs (Noris et al, 2007) . Tregs are a subset of T lymphocytes that suppress the activation of the immune system and increasing Treg numbers may improve autoimmune diseases (Brusko et al, 2008) . Interestingly, some evidence suggests that peripheral blood DNTs may be dysregulated Tregs, while other evidence suggests they are cytotoxic T lymphocytes that have lost CD8 expression (Bleesing et al, 2001; Fischer et al, 2005) . We have found mTOR inhibition decreases these abnormal DNTs in ALPS patients. Sirolimus has been shown to increase Tregs in healthy volunteers and patients with other autoimmune diseases (Battaglia et al, 2006) . These observations, taken together, suggest the possibility that the improved responses with sirolimus seen here compared to other immunosuppressive agents, both in preclinical models and in patients, may be attributable to both induction of apoptosis in the abnormal lymphocytes and increases in normal Tregs. In subsequent patients, we plan to measure Tregs before and after initiating treatment with sirolimus. Unfortunately, as DNTs do not survive in culture, we could not directly test the in-vitro sensitivity of ALPS-patient's DNTs to sirolimus.
As sirolimus can cause lymphocyte apoptosis and increase Tregs, it may also have activity in non-ALPS patients with autoimmune cytopenias, including patients with immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia (AIHA) and autoimmune neutropenia, either as isolated idiopathic conditions or when associated with other autoimmune syndromes, including lupus or Evans syndrome. Our findings suggest that sirolimus may be superior to other agents currently used for or being investigated in these syndromes, including mercaptopurine, MMF, cyclosporine and tacrolimus. None of these agents are both lymphotoxic to both B and T cells while simultaneously increasing Tregs. Accordingly, we plan to open a clinical trial investigating the efficacy of sirolimus in patients with chronic ITP and chronic AIHA.
We found sirolimus was very effective in ameliorating autoimmune disease and lymphoproliferation in patients with ALPS, corroborating our previous preclinical work. Based on these results, we plan to continue to treat patients with ALPS and either steroid-refractory disease or who are steroidintolerant with sirolimus and we have initiated a phase II efficacy trial of sirolimus in ALPS. Based on this trial, we anticipate that sirolimus may move to the frontline of therapy for patients with ALPS.
